These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 15844319)

  • 1. Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy.
    Sun D; Feng JM; Zhao YL; Jin T; Wang LN
    Chin Med Sci J; 2005 Mar; 20(1):67-9. PubMed ID: 15844319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of prostaglandin E1 on renal microvascular injury in rats of acute aristolochic acid nephropathy.
    Sun D; Liu CX; Ma YY; Zhang L
    Ren Fail; 2011; 33(2):225-32. PubMed ID: 21332345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute kidney injury induced by aristolochic acid in patients with primary glomerular nephritis.
    Tang Z; Chen D; Zhang Y; Chen Z; Chen H; Zeng C; Liu Z
    Ren Fail; 2014 Apr; 36(3):367-71. PubMed ID: 24344833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy.
    Vanherweghem JL; Abramowicz D; Tielemans C; Depierreux M
    Am J Kidney Dis; 1996 Feb; 27(2):209-15. PubMed ID: 8659495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy.
    Sun D; Feng J; Dai C; Sun L; Jin T; Ma J; Wang L
    Am J Nephrol; 2006; 26(4):363-71. PubMed ID: 16873992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristolochic acid nephropathy: variation in presentation and prognosis.
    Yang L; Su T; Li XM; Wang X; Cai SQ; Meng LQ; Zou WZ; Wang HY
    Nephrol Dial Transplant; 2012 Jan; 27(1):292-8. PubMed ID: 21719716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence and analysis of low-dosage steroid therapy in severe aristolochic acid nephropathy patients.
    Ma DH; Zheng FL; Su Y; Li MX; Guo MH
    Nephrology (Carlton); 2016 Oct; 21(10):835-40. PubMed ID: 26609908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs.
    Hong YT; Fu LS; Chung LH; Hung SC; Huang YT; Chi CS
    Pediatr Nephrol; 2006 Apr; 21(4):577-9. PubMed ID: 16520953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Case of traditional herbal medicine-induced aristolochic acid nephropathy developing to end-stage renal failure].
    Fujimura T; Tamaki K; Iida S; Tanaka H; Ikedou H; Takamiya Y; Kato S; Tanaka A; Okuda S
    Nihon Jinzo Gakkai Shi; 2005; 47(4):474-80. PubMed ID: 15971892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aristolochic acid-induced accumulation of methylglyoxal and Nε-(carboxymethyl)lysine: an important and novel pathway in the pathogenic mechanism for aristolochic acid nephropathy.
    Li YC; Tsai SH; Chen SM; Chang YM; Huang TC; Huang YP; Chang CT; Lee JA
    Biochem Biophys Res Commun; 2012 Jul; 423(4):832-7. PubMed ID: 22713464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An analysis of the clinical and pathological characteristics of mu-tong (a Chinese herb) induced tubulointerstitial nephropathy].
    Li X; Yang L; Yu Y
    Zhonghua Nei Ke Za Zhi; 2001 Oct; 40(10):681-7. PubMed ID: 11769723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective role of relaxin in a mouse model of aristolochic acid nephropathy.
    Yang X; Thorngren D; Chen Q; Wang M; Xie X
    Biomed Pharmacother; 2019 Jul; 115():108917. PubMed ID: 31060002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy.
    Wu Y; Liu Z; Hu W; Li L
    Hum Exp Toxicol; 2005 Feb; 24(2):41-7. PubMed ID: 15850277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential changes of intrarenal oxygenation in rat models of acute tubular necrosis caused by aristolochic acid and gentamicin].
    Cao J; Yang XD; Wang XY; Qu L; Liu G; Li XM
    Zhonghua Yi Xue Za Zhi; 2010 May; 90(17):1208-12. PubMed ID: 20646571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical effect of treatment with lipo-prostaglandin E1 on the patients with chronic glomerulonephritis].
    Zhong WQ; Liu GX; Yang YM; Cai X; Huang ZL
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 May; 16(5):292-4. PubMed ID: 15132795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy.
    Kazama I; Matsubara M; Michimata M; Suzuki M; Hatano R; Sato H; Ito S
    Clin Exp Nephrol; 2004 Sep; 8(3):283-7. PubMed ID: 15480910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E1 attenuation of ischemic renal reperfusion injury in the rat.
    Vargas AV; Krishnamurthi V; Masih R; Robinson AV; Schulak JA
    J Am Coll Surg; 1995 Jun; 180(6):713-7. PubMed ID: 7773485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice.
    Huang TC; Chen SM; Li YC; Lee JA
    Biomed Chromatogr; 2013 Sep; 27(9):1100-6. PubMed ID: 23553367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.
    Sketch MH; Whelton A; Schollmayer E; Koch JA; Bernink PJ; Woltering F; Brinker J;
    Am J Ther; 2001; 8(3):155-62. PubMed ID: 11344383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical and pathological manifestations of aristolochic acid nephropathy--the report of 58 cases].
    Chen W; Chen Y; Li A
    Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(18):1101-5. PubMed ID: 11766606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.